neuroFix Therapeutics Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

neuroFix Therapeutics General Information

Description

Developer of therapeutic products. The company develops NFC-1 a non-stimulant metabotropic glutamate receptor for the treatment of mGluR network mutation positive attention deficit hyperactivity disorder and neuropsychiatric symptoms in USA.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • DE
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

neuroFix Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore neuroFix Therapeutics‘s full profile, request access.

Request a free trial

neuroFix Therapeutics Patents

neuroFix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-2745707-B1 Spinal osteosynthesis device Expired - Fee Related 05-Mar-1996 00000000000
FR-2745707-A1 Spinal osteosynthesis device Granted 05-Mar-1996 00000000000 0
AU-1199297-A Spinal osteosynthesis device Abandoned 05-Mar-1996 00000000000
EP-0884979-A1 Spinal osteosynthesis device Withdrawn 05-Mar-1996 A61B17/7026

neuroFix Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Hakon Hakonarson Ph.D Founder
To view neuroFix Therapeutics’s complete executive team members history, request access »